Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3Tumor-Agnostic 2Gastrointestinal 2Dermatologic 2

Conditions

Solid Tumors 2Advanced/Metastatic Solid Tumors 1

Interventions

Cisplatin 81Gemcitabine 58Carboplatin 57Irinotecan 56Paclitaxel 53Pemetrexed 47Docetaxel 39Nivolumab 33Fluorouracil 30Bevacizumab 27pembrolizumab 25Cyclophosphamide 24Capecitabine 24Oxaliplatin 22Leucovorin 21Topotecan 19durvalumab 17Erlotinib Hydrochloride 17Sorafenib 16Everolimus 16Etoposide 16Bortezomib 16Ipilimumab 15Injections 15Sunitinib 14Filgrastim 14Early Intervention, Educational 14atezolizumab 13alvocidib 13Sirolimus 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × selicrelumab × Other solid neoplasm × Clear all
NCT02665416 2020-04-07

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
94 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT02304393 2019-12-13

A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
140 enrolled
Other solid neoplasm

Solid Tumors

NCT02157831 2018-08-17

Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors

Abramson Cancer Center at Penn Medicine

Phase EARLY_PHASE1 Completed
10 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡